Premium
A case of tumour necrosis factor‐α inhibitor‐ and rituximab‐induced plantar pustular psoriasis that completely resolved with tocilizumab
Author(s) -
Jayasekera P.,
Parslew R.,
AlSharqi A.
Publication year - 2014
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.13146
Subject(s) - medicine , rituximab , tocilizumab , rheumatoid arthritis , psoriasis , psoriatic arthritis , tumor necrosis factor alpha , monoclonal , methotrexate , dermatology , arthritis , monoclonal antibody , immunology , antibody
Summary Rituximab, a chimeric B ‐cell‐depleting monoclonal antibody, is a well‐established therapy for rheumatoid arthritis. It is emerging that classical psoriatic lesions and plantar pustular psoriasis ( PPP ) are cutaneous side‐effects of this drug. Antitumour necrosis factor (anti‐ TNF ) therapies have multiple documented side‐effects including PPP and psoriasis. We report a patient who has rheumatoid arthritis, who failed on anti‐ TNF therapies and then was commenced on rituximab. Subsequently she developed localized PPP . Due to deterioration of her joint disease she was switched to the interleukin‐6 blocker tocilizumab, and the PPP resolved.